Diabetic Nephropathies

Heart Failure

Hypertension

Myocardial Infarction

Ventricular Dysfunction, Left

<section class="Section" data-sectioncode="34089-3"><a name="ID_f6e0465a-5695-414d-a935-db40c770383d"></a><a name="section-10"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Lisinopril is an oral long-acting angiotensin converting enzyme (ACE) inhibitor. Lisinopril is a synthetic peptide derivative that is manufactured as a dihydrate and is chemically described as 1-[   <span class="Italics">N</span><span class="Sup">2</span>-[(   <span class="Italics">S</span>)-1-Carboxy-3-phenylpropyl]-L-lysyl]-L-proline dihydrate. Its molecular formula is C   <span class="Sub">21</span>H   <span class="Sub">31</span>N   <span class="Sub">3</span>O   <span class="Sub">5</span>·2H   <span class="Sub">2</span>O and its structural formula is: </p><div class="Figure"><a name="id-1749886550"></a><img alt="Structural Formula" src="image-01.jpg"/></div><p>Lisinopril is a white to off-white, crystalline powder, with a molecular weight of 441.52 (for dihydrate). It is soluble in water, sparingly soluble in methanol, and practically insoluble in ethanol.</p><p>QBRELIS (lisinopril), 1 mg/mL, is a ready-to-use aqueous formulation. Each 1 mL of the oral solution contains 1.09 mg of lisinopril dihydrate, which is equivalent to 1 mg of lisinopril as the active ingredient and the following inactive ingredients: purified water, xylitol, sodium citrate, citric acid, sodium benzoate, and either hydrochloric acid or sodium hydroxide which may be added for pH adjustment. The solution is clear to slightly opalescent. The pH of the solution ranges from 4.3 to 5.1. QBRELIS is supplied as 150 mL of the solution packaged in a 150-mL round, white, opaque, high-density polyethylene (HDPE) bottle with a white, polypropylene, child-resistant closure with a heat induction layered inner seal.</p></section>

Qbrelis

lisinopril 1 MG/ML Oral Solution

lisinopril 1 MG/ML Oral Solution [Qbrelis]

lisinopril

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event

Prescribing Information

Submit MSL Request 

Pharmacy List 

Coverage Authorization Request 

Coverage Authorization Appeals 

Enroll in Patient Savings Program 

Bridge Program 

Qbrelis Enrollment & Prescription Form 

About Qbrelis 

Instructions For Use: Hypertension